News
In calling for more clinical testing of vaccines in younger people and those who face a low risk of severe disease from Covid ...
9d
Mens Fitness on MSNNew Study Finds This Common Supplement Cuts Dementia Risk by 40 PercentNew research offers promising hope in the battle against cognitive decline. Biochemist Rhonda Patrick shared a study ...
“Many of the observed associations linking greater sedentary time with brain health and cognitive outcomes were present in ...
Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering ...
17d
MedPage Today on MSNSedentary Time Tied to Brain Volume, Worse Cognition in Older Adults"These findings suggest that above and beyond physical activity level, more sedentary behavior is still worse for brain health and cognition over time," Gogniat told MedPage Today ...
ApoE4 carriers have a substantially higher risk of developing ARIA, so Alzheimer’s patients who carry this genetic variant could benefit from a drug offering a different approach. While Leqembi ...
Topline results were announced from a phase 3 trial evaluating valiltramiprosate (ALZ-801) in apolipoprotein ε4 allele (APOE4) carriers with early Alzheimer disease (AD). Valiltramiprosate is an ...
For Parkinson’s, we will take a deeper look into the cognitive response, while for Alzheimer’s, we will dive into the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in ...
1Hey JA, et al: Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a Two-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease, Clinical Pharmacokinetics 2025.
Among APOE4 carriers, women had significantly faster tau deposits in the inferior-temporal region. Sex differences in tau may help explain why women face higher Alzheimer's dementia risk than men.
Valiltramiprosate Phase 2 Biomarker Trial Biomarker Effects of Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease (NCT04693520): This trial was designed to evaluate the effects of ...
Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results